

CLAIMS

1. A composition comprising geranium oil and extractions from the root of *Sophora tonkinesis*.
2. The composition of claim 1, wherein the geranium oil and extractions from the root of *Sophora tonkinesis* have a weight ratio of about 30:1.
3. The composition of claim 1, wherein the composition comprises a mixture of powders of geranium oil and powders of extractions from the root of *Sophora tonkinesis*.
4. The composition of claim 3, wherein the powders of geranium oil is about 56% of the mixture of powders.
5. The composition of claim 4, wherein the powders of geranium oil comprise geranium oil at about 31% by weight and excipients at about 69% by weight.
6. The composition of claim 3, wherein the powders of extractions from the root of *Sophora tonkinesis* is about 1% of the mixture of powders.
7. The composition of claim 6, wherein the powders of extractions from the root of *Sophora tonkinesis* comprises *Sophora tonkinesis* extractions at about 60% by weight and excipients at about 40% by weight.
8. The composition of claim 1, wherein the geranium oil is extracted from one or more species of the genus *Pelargonium*.
9. The composition of claim 1, wherein the geranium oil is extracted from a plant of the genus *Pelargonium* and species *graveolens*.
10. The composition of claim 1, wherein the geranium oil is extracted from a plant of the genus *Pelargonium* and species *roseum*.

11. The composition of claim 1, wherein the geranium oil is extracted from a plant of the genus *Pelargonium* and species *terebinthineum*.

12. Use of a composition comprising geranium oil and extractions from the roots of *Sophora tonkinesis* for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

13. Use of a composition comprising citronellol, geraniol, geranyl formate, citronellyl formate, matrine, and oxymatrine for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

14. Use of a composition comprising citronellol, geraniol, geranyl formate, citronellyl formate, linalool, trans-rose oxide, cis-rose oxide, matrine, oxymatrine, and sophocarpine for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

15. Use of a composition comprising geranium oil, matrine, and oxymatrine for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

16. Use of a composition comprising extractions from the root of *Sophora tonkinesis*, citronellol, geraniol, citronellyl formate, and geranyl formate for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

17. The use of claim 12, wherein the bone marrow suppression is a reduction in the number of one or more types of blood cells selected from the group consisting of leukocytes, erythrocytes, and platelets.

18. The use of claim 12, wherein the one or more cancer treatments is chemotherapy, radiation therapy, or both chemotherapy and radiation therapy.

19. The use of claim 18, wherein the chemotherapy agent is 5-fluorouracil,

doxorubicin, or both 5-fluorouracil and doxorubicin.

20. The use of claim 12, wherein the treatment of bone marrow suppression is carried out through oral administration, intraperitoneal administration, or intravenous administration.

21. The use of claim 20, wherein the oral administration is carried out at a dosage in a range between about 280mg/kg/day and about 1050mg/kg/day.

22. The use of claim 21, wherein the oral administration is carried out at a dosage about 350mg/kg/day.

23. The use of claim 20, wherein the oral administration is carried out at a dosage in a range between about 1680mg/60kg/day and about 6300 mg/60kg/day.

24. The use of claim 23, wherein the oral administration is carried out at a dosage about 2100mg/60kg/day.

25. The use of claim 12, wherein the geranium oil and extractions from the root of *Sophora tokinesis* have a weight ratio of about 30:1.

26. The use of claim 12, wherein the treatment of bone marrow suppression is performed on humans.

27. The use of claim 20, wherein the oral administration is carried out by administering the composition in the form of powders, pastes, pills, tablets, oil capsules, syrup, liquids, or decoction soups.

28. The use of claim 20, wherein the oral administration is carried out by administering edible forms of *Pelargonium* plant and the root of *Sophora tonkinesis*.

29. The use of claim 12, wherein the geranium oil is extracted from one or more species of the genus *Pelargonium*.

30. The use of claim 12, 13, 14, 15, 16, 27, or 28, wherein the composition

further comprises a pharmaceutically acceptable solvent.

31. The use of claim 12, wherein the treatment of bone marrow suppression is carried out by administering the composition before, after, before and after, or during cancer treatments.

32. The use of claim 31, wherein the treatment of bone marrow suppression is carried out by administering the composition following a time interval between separate administrations.

33. The use of claim 32, wherein the time interval is one to fourteen days, within twenty-four hours, or within forty-eight hours.

34. Use of a composition comprising geranium oil and extractions from the roots of *Sophora tonkinesis* for the manufacture of a composition for oral consumption for preventing bone marrow suppression.

35. The use of claim 34, wherein the oral consumption is in the form of food additives, dietary supplement, or functional food.

36. Use of a composition comprising geranium oil and extractions from the roots of a Sophora plant for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.

37. The use of claim 36, wherein the Sophora plant is *Sophora alopecuroides* or *Sophora moorcroftiana*.

38. Use of a composition comprising geranium oil and extractions from the roots of *Euchresta strigillosa* for the manufacture of a medicament for the treatment of bone marrow suppression resulting from one or more cancer treatments.